Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	ICU Medical	Glaukos	Inari Medical	Cantel Medical	NuVasive
Symbol	NASDAQ:ICUI	NYSE:GKOS	NASDAQ:NARI	NYSE:CMD	NASDAQ:NUVA
Price Information
Current Price	$195.48	$74.38	$81.37	$83.93	$68.59
52 Week Range	Buy	Hold	Buy	Hold	Hold
MarketRank™
Overall Score	1.5	0.9	1.5	1.3	1.2
Analysis Score	2.5	1.0	4.4	1.0	1.2
Community Score	2.5	2.8	3.3	2.4	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	0.0	1.7	0.0
Earnings & Valuation Score	0.6	0.6	0.0	1.3	1.9
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Hold	Hold
Consensus Price Target	$240.50	$70.14	$117.17	$71.50	$68.43
% Upside from Price Target	23.03% upside	-5.70% downside	43.99% upside	-14.81% downside	-0.24% downside
Trade Information
Market Cap	$4.15 billion	$3.44 billion	$4.03 billion	$3.74 billion	$3.54 billion
Beta	0.72	1.87	N/A	1.54	1.36
Average Volume	123,297	421,321	580,405	511,980	712,722
Sales & Book Value
Annual Revenue	$1.27 billion	$236.98 million	N/A	$1.02 billion	$1.17 billion
Price / Sales	3.28	14.53	N/A	3.68	3.03
Cashflow	$10.39 per share	$0.14 per share	N/A	$3.70 per share	$6.72 per share
Price / Cash	18.81	537.71	N/A	22.69	10.20
Book Value	$66.62 per share	$18.50 per share	N/A	$17.31 per share	$17.58 per share
Price / Book	2.93	4.02	N/A	4.85	3.90
Profitability
Net Income	$101.04 million	$15.42 million	N/A	$13.71 million	$65.23 million
EPS	$7.36	($0.10)	N/A	$1.65	$2.47
Trailing P/E Ratio	51.71	N/A	0.00	99.92	N/A
Forward P/E Ratio	31.53	N/A	N/A	28.84	29.31
P/E Growth	N/A	N/A	N/A	1.57	1.79
Net Margins	6.43%	-33.61%	N/A	3.38%	-0.84%
Return on Equity (ROE)	9.73%	-7.99%	N/A	11.19%	8.00%
Return on Assets (ROA)	7.70%	-5.87%	N/A	4.10%	3.06%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	-25.00%	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.37%	N/A	1.28%	0.85%
Current Ratio	4.86%	9.73%	13.92%	3.13%	1.85%
Quick Ratio	3.12%	9.31%	13.42%	2.31%	1.48%
Ownership Information
Institutional Ownership Percentage	91.49%	N/A	17.77%	95.01%	N/A
Insider Ownership Percentage	10.90%	8.70%	N/A	10.70%	0.89%
Miscellaneous
Employees	7,900	653	456	3,669	2,700
Shares Outstanding	21.22 million	46.28 million	49.58 million	44.51 million	51.65 million
Next Earnings Date	8/9/2021 (Estimated)	8/5/2021 (Estimated)	8/10/2021 (Estimated)	6/3/2021 (Estimated)	8/3/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	Huge Demand of Orthopaedic Prosthetics Market by 2027 \| Wright Medical, NuVasive Inc., DJO Global – Test & Measurement - Test & Measurement testmeasurement.com.au - May 13 at 1:45 PM
	Interspinous Spacers Market 2021 Predictive Analytics \|Paradigm Spine (Rti Surgical), Nuvasive Inc, Globus Medical Inc, Medtronic, Zimmer Biomet – The Manomet Current - The Manomet Current manometcurrent.com - May 13 at 1:45 PM
	MCRA CRO Assists Simplify Medical, Recently Acquired by NuVasive, on FDA-Approval for Two Level use of its Cervical Disc - BioSpace biospace.com - May 13 at 1:45 PM
	Morgan Stanley Raises NuVasive (NASDAQ:NUVA) Price Target to $74.00 americanbankingnews.com - May 13 at 12:48 PM
	NuVasive (NASDAQ:NUVA) PT Raised to $74.00 marketbeat.com - May 13 at 8:46 AM
	Here's Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Looks Fair for the time being - Yahoo Finance finance.yahoo.com - May 12 at 2:58 PM
	MCRA CRO Assists Simplify Medical, Recently Acquired by NuVasive, on FDA-Approval for Two Level use of its Cervical Disc - PRNewswire prnewswire.com - May 12 at 2:58 PM
	Piper Sandler Raises NuVasive (NASDAQ:NUVA) Price Target to $80.00 americanbankingnews.com - May 12 at 11:02 AM
	Spinal Fixation Product Market 2021 Strategic Assessments – Medtronic, J & J, NuVasive, Stryker, Globus Medical, Zimmer Biomet, Orthofix International – The Shotcaller - The Shotcaller theshotcaller.net - May 12 at 9:58 AM
	Here's Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Looks Fair for the time being finance.yahoo.com - May 12 at 9:58 AM
	Needham & Company LLC Boosts NuVasive (NASDAQ:NUVA) Price Target to $80.00 americanbankingnews.com - May 12 at 9:38 AM
	Piper Sandler Weighs in on NuVasive, Inc.'s Q3 2021 Earnings (NASDAQ:NUVA) americanbankingnews.com - May 12 at 3:14 AM
	Targeted communication: CE mark suspended for all MAGEC systems manufactured by NuVasive Specialized Orthopedics, Inc. - GOV.UK gov.uk - May 11 at 11:10 PM
	NuVasive, Inc. (NASDAQ:NUVA) EVP Sells $231,913.77 in Stock americanbankingnews.com - May 11 at 9:07 PM
	NuVasive, Inc. (NASDAQ:NUVA) Insider Lucas Vitale Sells 2,208 Shares americanbankingnews.com - May 11 at 9:07 PM
	Let's talk robots: 9 CEO insights from Medtronic, Stryker & more - Becker's Orthopedic & Spine beckersspine.com - May 11 at 1:09 PM
	NuVasive Appoints Juliet C. Cunningham as Vice President of Investor Relations - PRNewswire prnewswire.com - May 10 at 4:12 PM
	NuVasive Appoints Juliet C. Cunningham as Vice President of Investor Relations finance.yahoo.com - May 10 at 4:12 PM
	Brokers Offer Predictions for NuVasive, Inc.'s Q3 2021 Earnings (NASDAQ:NUVA) americanbankingnews.com - May 10 at 3:06 AM
	Leerink Partners Stick to Their Buy Rating for Nuvasive By Investing.com - Investing.com investing.com - May 9 at 9:29 AM
	NuVasive (NUVA) Q1 Earnings Top Estimates, Gross Margin Up - Nasdaq nasdaq.com - May 8 at 1:35 PM
	Analysts Conflicted on These Healthcare Names: ACADIA Pharmaceuticals (ACAD), Inotiv (NOTV) and NuVasive (NUVA) - Smarter Analyst smarteranalyst.com - May 8 at 8:04 AM
	Have Insiders Been Buying NuVasive, Inc. (NASDAQ:NUVA) Shares? finance.yahoo.com - May 7 at 3:16 PM
	Morgan Stanley Increases NuVasive (NASDAQ:NUVA) Price Target to $74.00 americanbankingnews.com - May 7 at 11:58 AM
	NuVasive: Q1 Earnings Snapshot - New Haven Register nhregister.com - May 7 at 10:16 AM
	NuVasive (NASDAQ:NUVA) Price Target Raised to $74.00 marketbeat.com - May 7 at 9:16 AM
	NuVasive (NUVA) Q1 Earnings Top Estimates, Gross Margin Up - Yahoo Finance finance.yahoo.com - May 6 at 11:01 PM

Date	Company	Brokerage	Action
3/4/2021	ICU Medical	Raymond James	Boost Price Target
1/8/2021	ICU Medical	KeyCorp	Boost Price Target
3/31/2020	ICU Medical	CJS Securities	Upgrade
5/6/2021	Glaukos	Oppenheimer	Boost Price Target
1/29/2021	Glaukos	Piper Sandler	Downgrade
12/16/2020	Glaukos	Smith Barney Citigroup	Upgrade
12/16/2020	Glaukos	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Upgrade
11/17/2020	Glaukos	Wells Fargo & Company	Upgrade
10/8/2020	Glaukos	JPMorgan Chase & Co.	Downgrade
6/15/2020	Glaukos	Jefferies Financial Group	Initiated Coverage
5/8/2020	Glaukos	Stifel Nicolaus	Lower Price Target
3/23/2020	Glaukos	Stephens	Lower Price Target
1/6/2020	Glaukos	Berenberg Bank	Upgrade
5/12/2021	Inari Medical	Morgan Stanley	Boost Price Target
5/12/2021	Inari Medical	Canaccord Genuity	Boost Price Target
3/16/2021	Inari Medical	SVB Leerink	Boost Price Target
3/10/2021	Inari Medical	BTIG Research	Boost Price Target
6/16/2020	Inari Medical	Bank of America	Initiated Coverage
1/13/2021	Cantel Medical	Needham & Company LLC	Downgrade
1/12/2021	Cantel Medical	Sidoti	Downgrade
4/27/2021	NuVasive	Truist	Boost Price Target

(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources